Company Product Description Indication Status
Phase I
Achilles Therapeutics Inc., of Stevenage, U.K. T-cell therapy Tumor-infiltrating lymphocyte therapy Recurrent or metastatic malignant melanoma Dosed first patient in phase I/II study expected to recruit about 20 patients and report initial data in first half of 2021
Aveo Oncology Inc., of Boston Fotivda (tivozanib) VEGF receptor tyrosine kinase inhibitor Hepatocellular carcinoma Phase Ib/II Deductive trial in combination with Imfinzi (durvalumab, Astrazeneca), in patients who have not received prior systemic therapy, demonstrated the combination can be administered safely; study has progressed to the phase II portion
Bio-Path Holdings Inc., of Houston, Texas BP-1001 Liposomal Grb2 antisense oligonucleotide  Philadelphia chromosome-positive chronic myelogenous leukemia  Phase I/II study in combination with dasatinib withdrawn with no enrollment
Corvus Pharmaceuticals Inc., of Burlingame, Calif. Ciforadenant Adenosine A2A receptor antagonist Renal cell carcinoma New data support and refine the utility ofadenosine gene signature (Adenosig) as a predictive biomarker to identify RCC patients most likely to respond to treatment with ciforadenant; in 30 patients with available tumor biopsies, Adenosig-positive patients had 17% objective response rate (ORR) by RECIST criteria compared to 0% in Adenosig-negative patients; in new data that covers 51 RCC patients treated with ciforadenant monotherapy or in combination with Tecentriq (atezolizumab, Roche), and whose tumors were biopsied to test with the Adenosig, ORR remained 17% for the adenosine gene signature and improved to 27% with the refined version of the test, which is based on the measurement of CD68-positive myeloid cells, the downstream target of adenosine
Molecular Partners AG, of Zurich, Switzerland MP-0250 Multidomain DARPin candidate Non-small-cell lung cancer Phase I/II trial testing combination with Tagrisso (osimertinib, Astrazeneca plc) in patients with EGFR-mutated disease terminated at sponsor’s decision
Phase II
Adverum Biotechnologies Inc., of Redwood City, Calif. ADVM-022 AAV-based gene therapy Diabetic macular edema Started double-masked Infinity trial vs. Eylea (aflibercept, Regeneron Pharmaceuticals Inc.); will assess time to worsening of DME
Bristol Myers Squibb Co., of New York Opdivo (nivolumab) Anti-PD-1 monoclonal antibody Non-small-cell lung cancer Checkmate 9TN study testing nivolumab after surgery in patients with minimal residual disease withdrawn prior to patient recruitment due to change in business objectives
Bristol Myers Squibb Co., of New York Opdivo (nivolumab) Anti-PD-1 monoclonal antibody Stage III/IV head and neck squamous cell carcinoma Study testing combination with carboplatin and paclitaxel in patients with HNSCC that can be removed by surgery suspended due to COVID-19
Chiesi Farmaceutici SpA, of Parma, Italy Nebulized Curosurf (poractant alfa) Pulmonary surfactant Respiratory distress syndrome in preterm neonates Terminated due to change in risk-benefit balance
Eloxx Pharmaceuticals Inc., of Waltham, Mass. ELX-02 Eukaryotic ribosomal selective glycoside Nephropathic cystinosis Due to study design limitations, trial discontinued and will not proceed with second cohort
Galera Therapeutics Inc., of Malvern, Pa. Avasopasem manganese Superoxide dismutase stimulator  Oral mucositis Post-treatment kidney function markers indicated patients who received 90 mg of avasopasem in phase IIb study had significantly less cisplatin-induced chronic kidney disease vs. placebo
Phase III
Janssen Research & Development LLC, a unit of New Brunswick, N.J.-based Johnson & Johnson Guselkumab Antibody blocking IL-23 Chronic plaque psoriasis Enrollment on hold in Protostar study in pediatric patients due to COVID-19
Minerva Neurosciences Inc., of Waltham, Mass. Roluperidone  Dual 5-HT2A /sigma 2 antagonist Schizophrenia Trial evaluating drug's power to  treat negative symptoms in schizophrenia missed its primary endpoint (reduction in PANSS Marder Negative Symptoms Factor Score or NSFS) and key secondary endpoints 
Myovant Sciences Ltd., of Basel, Switzerland Relugolix  Oral gonadotropin-releasing hormone receptor antagonist Prostate tumor Further findings from Hero study found superiority of relugolix vs. leuprolide acetate, with additional data on testosterone suppression and recovery and prostate-specific antigen response; relugolix treatment showed 54% lower risk of MACE vs. leuprolide acetate 

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments